$IOBT reports impressive results for T-win® cancer vaccine & launches pivotal Phase 3 study
Mar 14th 2023, 10:09 am
Analyst Summary: IO Biotech has made progress in developing its T-win® immune-modulating cancer vaccines, which have the potential to become the backbone of therapy for multiple cancer types. In the Phase 1/2 study of IO102-IO103, the vaccine induced meaningful tumor regression and established durable antitumor response while achieving a favorable safety profile for patients. The vaccine provided activity across PD-L1 subgroups, validating its mechanism of action. IO Biotech is launching a Phase 3 pivotal study of IO102-IO103 in which the vaccine has the potential to significantly improve the current treatment paradigm. The company's cash position is strong, with runway through 3Q2024. With early-stage pipeline targeting additional immune suppressive mechanisms, the opportunities for growth are significant.